Company news

NovoCure Limited news in 2024

NovoCure Limited's news releases, calls and decks from 2024, newest first.

View company

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

December 1, 2024

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

December 1, 2024

Novocure to Participate in Upcoming Investor Conferences

November 26, 2024

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

November 20, 2024

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

November 20, 2024

Novocure Reports Third Quarter 2024 Financial Results

October 29, 2024

Novocure Appoints Christoph Brackmann as Chief Financial Officer

October 29, 2024

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

October 14, 2024

Novocure to Report Third Quarter 2024 Financial Results

September 30, 2024

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

September 8, 2024

Novocure Announces Planned CEO Transition

September 2, 2024

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

August 27, 2024

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

August 13, 2024

Novocure Reports Second Quarter 2024 Financial Results

July 24, 2024

Novocure to Report Second Quarter 2024 Financial Results

June 30, 2024

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

June 2, 2024

TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany

May 22, 2024

Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

May 1, 2024

Novocure Reports First Quarter 2024 Financial Results

May 1, 2024

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

April 23, 2024

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

April 4, 2024

Novocure to Report First Quarter 2024 Financial Results

March 31, 2024

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

March 26, 2024

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

March 10, 2024

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

February 21, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

January 17, 2024

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

January 8, 2024

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

January 7, 2024

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

January 3, 2024

Calls in 2024

Decks in 2024